Global Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Regional Forecasts 2022-2032

Global Preimplantation Genetic Diagnosis Market Size Study, by Test Type (Chromosomal Abnormalities, Aneuploidy, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, Others) and Regional Forecasts 2022-2032

Global Preimplantation Genetic Diagnosis Market is valued at approximately USD 72.12 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.41% over the forecast period 2024-2032. Preimplantation Genetic Diagnosis (PGD) is a sophisticated reproductive technology used with In Vitro Fertilization (IVF) to screen embryos for genetic conditions before implantation. This process helps couples at risk of passing on inherited genetic disorders increase their chances of having a healthy child. The IVF process involves hormonal treatments, egg retrieval, fertilization in a lab, and embryo culture to the blastocyst stage, where cells are biopsied and analyzed for genetic abnormalities. Embryos without defects are selected for transfer into the uterus. PGD reduces the transmission of genetic disorders, increases IVF success rates, and raises ethical considerations. It is beneficial for couples with a family history of genetic disorders, recurrent miscarriages, or fertility issues. The Global Preimplantation Genetic Diagnosis Market is growing due to increasing awareness of genetic disorders, advancements in reproductive technologies, rising acceptance of IVF procedures, and supportive government regulations. The trend of delayed parenthood and rising infertility rates also contribute to the demand for PGD, driving market growth.

The Global Preimplantation Genetic Diagnosis (PGD) market is driven by increasing awareness of genetic disorders, advancements in reproductive technologies, rising prevalence of inherited conditions, and growing acceptance of IVF procedures. Technological innovations, such as next-generation sequencing, have improved PGD's accuracy and efficiency, enabling broader detection of genetic abnormalities and reducing implantation failure and miscarriage risks. These advancements make PGD more reliable and accessible, encouraging more couples to use this technology for healthier offspring. However, high costs, ethical concerns regarding embryo selection, and the psychological impact on parents are significant barriers. Additionally, limited access to advanced reproductive technologies in developing regions and varying legal and ethical guidelines across countries pose challenges. Despite these, the supportive government regulations and funding for genetic research contribute to market growth, making PGD a valuable tool for ensuring the health of future generations.

The key regions considered for the Global Preimplantation Genetic Diagnosis market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the dominating region in terms of revenue in the Global Preimplantation Genetic Diagnosis (PGD) Market. The region boasts advanced healthcare infrastructure, allowing for widespread access to cutting-edge reproductive technologies. High adoption rates of PGD and IVF procedures are driven by increasing awareness of genetic disorders and the benefits of early genetic screening among prospective parents. Significant investments in research and development, coupled with supportive government policies and funding, foster continuous innovation and improvement in genetic testing methods. The presence of leading biotechnology companies and top-tier fertility clinics further enhances North America's market position. On the other hand, the market in Asia Pacific is expected to develop at the fastest rate over the forecast period.

Major market players included in this report are:
Natera Inc.
Agilent Technologies, Inc.
Reproductive Genetic Innovations, LLC
PerkinElmer, Inc.
Pacgenomics Inc
Quest Diagnostics Inc.
Laboratory Corporation of America Holdings,
Cegat Gmbh
Invitae Corp.
Illumina Inc.

The detailed segments and sub-segments of the market are explained below:

By Test Type
Chromosomal Abnormalities
Aneuploidy
X-linked diseases
Single Gene Disorders
HLA Typing
Gender selection
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.